<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02120274</url>
  </required_header>
  <id_info>
    <org_study_id>DB12SHCV</org_study_id>
    <secondary_id>U1111-1155-6986</secondary_id>
    <nct_id>NCT02120274</nct_id>
  </id_info>
  <brief_title>Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C</brief_title>
  <official_title>Randomized Clinical Trial to Assess the Effectiveness of Vitamin D and Vitamin B12 Supplementation in Combination With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of the supplementation of vitamins&#xD;
      D and B12 in combination with Pegylated Interferon-Alfa and Ribavirin in the treatment of&#xD;
      genotype 1 chronic hepatitis C, who do not qualify to receive protease inhibitor in Brazil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized clinical trial comparing rates of RVR, eRVR, EOT and SVR during standard treatment&#xD;
      with Pegylated Interferon-Alfa plus Ribavirin compared to the same treatment supplemented&#xD;
      with B12 and vitamin D during the treatment period.&#xD;
&#xD;
      Patients assigned to the vitamin supplementation group will receive the standard treatment of&#xD;
      Pegylated Interferon-Alfa plus Ribavirin for 48 weeks together oral Vitamin D and&#xD;
      intramuscular Vitamin B12. The control group will receive the same regimen of peguilated&#xD;
      alfainterferon plus ribavirin for 48 weeks without any vitamin supplementation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    New Brazilian Guidelines for Viral Hepatitis C and Coinfetions. It does not include the&#xD;
    treatment of chronic HCV Metavir &lt; F3 and abandon the use of interferon.&#xD;
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12</measure>
    <time_frame>12 weeks after treatment completion</time_frame>
    <description>Proportion of patients with SVR, defined as HCV RNA bellow the limit of detection 12 weeks after treatment completion with peguilated alfainterferon-2B plus ribavirin, with or without vitamin supplementation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RVR, EVR, EOT</measure>
    <time_frame>week 4, week 12 and at the end-of-treatment.</time_frame>
    <description>Proportion of patients presenting HCV RNA bellow the limit of detection at week 4 (RVR), week 12 (EVR - early virological response) and at the end-of-treatment (EOT);</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>RNA Virus Infections</condition>
  <condition>Flaviviridae Infections</condition>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pegylated Interferon-Alfa plus ribavirin for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamins</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegylated Interferon-Alfa plus ribavirin for 48 weeks together oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level. Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.</description>
    <arm_group_label>Vitamins</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin B 12</intervention_name>
    <description>Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.</description>
    <arm_group_label>Vitamins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genotype 1 HCV infection confirmed a positive test for anti-HCV antibody and&#xD;
             detectable serum HCV RNA by PCR&#xD;
&#xD;
          -  Pegylated Interferon-Alfa treatment naïve&#xD;
&#xD;
          -  Liver biopsy with Metavir F2 or less&#xD;
&#xD;
          -  Cognitive capacity to understand and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HBV or HIV co-infection&#xD;
&#xD;
          -  Hemoglobin level less than 10 g/dL or total neutrophil count less than 1,500/mm3 or&#xD;
             platlet count below 75,000/mm3&#xD;
&#xD;
          -  Creatinin ≥ 1.5 mg/dL&#xD;
&#xD;
          -  Severe cardiopathy&#xD;
&#xD;
          -  Pregnancy or impossibility to use birth control methods by the couple, or&#xD;
             breast-feeding&#xD;
&#xD;
          -  Conditions that, according to the investigator's judgement, preclude participation in&#xD;
             the study, including clinical, cognitive or behavioural conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adauto Castelo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge F Senise, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Outpatient Clinic of Viral Hepatitis (NUPAIG)</name>
      <address>
        <city>São Paulo</city>
        <zip>04025-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>April 18, 2014</study_first_submitted>
  <study_first_submitted_qc>April 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2014</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Henrique Pott Junior</investigator_full_name>
    <investigator_title>Dr. Henrique Pott-Junior</investigator_title>
  </responsible_party>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Flaviviridae Infections</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C, Chronic</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Vitamin B 12</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>RNA Virus Infections</mesh_term>
    <mesh_term>Flaviviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

